These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38112541)

  • 1. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
    Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
    Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
    Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
    Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.
    Mendiratta-Lala M; Aslam A; Maturen KE; Westerhoff M; Maurino C; Parikh ND; Sun Y; Sonnenday CJ; Stein EB; Shampain KL; Kaza RK; Cuneo K; Masch W; Do RKG; Lawrence TS; Owen D
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):704-714. PubMed ID: 34644607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.
    Zhang Y; Wang J; Li H; Zheng T; Jiang H; Li M; Song B
    Ann Transl Med; 2020 Mar; 8(6):388. PubMed ID: 32355832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
    Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
    Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
    Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
    Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
    Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.
    Cools KS; Moon AM; Burke LMB; McGinty KA; Strassle PD; Gerber DA
    Liver Transpl; 2020 Feb; 26(2):203-214. PubMed ID: 31677319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
    Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
    Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
    Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
    AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.